Category: Money tips Release Date: 2007-05-20
Source: Hong Kong and Macao Information Author: Xu Bo
Huahai (600,521): Corporate profit growth mainly in Plymouth Products Division for further expansion of production capacity, southern Sichuan raw material medicine production base of AIDS ritonavir series and put into trial production of intermediates losartan, irbesartan, and paroxetine in domestic sales agents increasingly heavy volume. Excellent performance of the company, competitive advantages are obvious. Trend, the stock continued to Suliang adjustment afternoon there is still room, we recommend investors continue to pay attention.
Historical Information: G Huahai (600,521): the concept of blue-chip accelerated repurchase pulled around the corner July 19, 2006
Source: Ningbo Shun
Index consecutive 11-yang, the market began to shift hot spot. With a very positive impact on the market the latter part of the policy of the gradual introduction of the market continues strong rise in market outlook is still worth looking forward to. Proposes a focus on G Huahai (600,521), the company is an international large-scale production can be simultaneously captopril, enalapril, lisinopril, one of a small number of manufacturers, and technological advantages are obvious, and the company's Plymouth products in the international market share, highest in the world, the market prospect is very broad.
Size, cost advantages of a very prominent
Company's leading products in the international market size and cost advantages are very obvious. Company's current products are raw material medicine or pharmaceutical intermediates, is an international large-scale production can be the same time, captopril, enalapril, lisinopril, one of a small number of manufacturers, Plymouth output of products and international markets share, highest in the world, the international market share of about 20% -30%. Plymouth Products With further expansion of production capacity, southern Sichuan raw material medicine production base of AIDS ritonavir series and put into trial production of intermediates losartan, irbesartan, and paroxetine in preparation gradually heavy volume of domestic sales and other factors, the company is expected to further establish its raw materials in the international drug market leading position.
Room for growth in a broad blue-chip pharmaceutical
The past few years, the company has maintained rapid growth momentum of development. As the characteristics of generic drugs at lower raw material medicine, so long-term development perspective, from the characteristics of the transfer of bulk drugs to generic drugs is imperative to follow this path. In this process of industrial upgrading, the company's production capacity, market trends, the technical reserve three products for the building of preparations made full preparations for the production chain. The same time, sales agents, a good positioning in the international market for its pioneering adds even greater advantage. From the company reported first quarter of 2006 terms, the company realized main business income of 123.963 million yuan, an increase of 21.15%; main business profit of 63.033 million yuan, an increase of 11.29%; to achieve net profit of 32.876 million yuan, an increase of 6.07% ; Plymouth class and losartan drugs gross margin reached 50.33%, respectively, and 45.84%. As a pharmaceutical blue chip, the company is still very wide space for future growth.
G Unit's first big buy-back the concept of imagination
Company's previous stock repurchase had the SFC program, and on April 21, 2006 was adopted. After the implementation of the completion of repurchase, the company registered capital from 234 million yuan, the lowest reduced to 224 million yuan. Judging from a few days ago the company announced, as of May 31, 2006, the Company has repurchased 25 million shares outstanding, the market outlook is expected to accelerate the company's buy-back will be, but as the first concept of G has a buy-back shares of the Company, its back to theme will also purchase secondary market price of its enormous room for imagination.
The secondary market, as the scale and market strengths are very prominent in international raw material drug giants, the Unit has always been the main funding separate ways close attention. Quarterly Bulletin from the company a point of view, which not only are subjected to social security fund, led by large domestic institutions favor, also affected by Shen 10000 Paris Moritoshi selected securities investment funds, HSBC, Citigroup and other QFII funds attention. Technically, as the first buy-back only with the concept of bulk drugs blue chips, midline sound upside trend is established, short-term point of view, the Unit consecutive Xiaoyang, after a steady uplift of stock, short-term chip has been successfully locked, the market outlook is expected to immediately accelerate pulled Quotes started, it is recommended to focus on.
